ID   MCF-7/LetR-4
AC   CVCL_5A20
SY   MCF7/LetR-4; LetR-4
DR   cancercelllines; CVCL_5A20
DR   CancerTools; 152550
DR   Wikidata; Q54904372
DR   Ximbio; 152550
RX   PubMed=25625755;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:6413; Letrozole.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1D47 ! MCF-7/S0.5
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 14
//
RX   PubMed=25625755; DOI=10.3892/ijo.2015.2850;
RA   Hole S., Pedersen A.M., Hansen S.K., Lundqvist J., Yde C.W.,
RA   Lykkesfeldt A.E.;
RT   "New cell culture model for aromatase inhibitor-resistant breast
RT   cancer shows sensitivity to fulvestrant treatment and cross-resistance
RT   between letrozole and exemestane.";
RL   Int. J. Oncol. 46:1481-1490(2015).
//